Geisinger turns to se­quenc­ing

Health Data Management - - NEWSLINE - —G.S.

Geisinger is ex­pand­ing its pop­u­la­tion health ge­nomics pro­gram be­yond re­search and into rou­tine clin­i­cal prac­tice, ef­fec­tively en­abling the health­care or­ga­ni­za­tion’s pa­tients to be the first in the na­tion to have the se­quenc­ing of their DNA as part of stan­dard care. “Un­der­stand­ing the genome warn­ing sig­nals of ev­ery pa­tient will be an es­sen­tial part of well­ness plan­ning and health man­age­ment,” said David Fein­berg, MD, pres­i­dent and CEO of Geisinger. “Geisinger pa­tients will be able to work with their fam­ily physi­cian to mod­ify their life­style and min­i­mize risks that may be re­vealed. This fore­cast­ing will al­low us to pro­vide truly an­tic­i­pa­tory health­care.” Ac­cord­ing to Fein­berg, Geisinger will launch its clin­i­cal DNA se­quenc­ing initiative with a 1,000-pa­tient pi­lot pro­gram over the next six months. Once the pi­lot is com­pleted, the pro­gram will then be rolled out through­out its

sites in Penn­syl­va­nia and south­ern New Jer­sey. Geisinger’s MyCode Com­mu­nity Health Initiative—a pre­ci­sion medicine re­search ef­fort launched in 2007 by the Danville, Penn.-based health sys­tem—will serve as the model for in­te­grat­ing ge­nomics and data science into ev­ery­day pre­ven­tive care at the provider or­ga­ni­za­tion. The MyCode Com­mu­nity Health Initiative, which has en­rolled more than 200,000 par­tic­i­pants, has iden­ti­fied more than 500 pa­tients who are at in­creased risk and has un­cov­ered pre­vi­ously un­de­tected cases of cancer and heart disease, en­abling its physi­cians to treat them much ear­lier than they could have other­wise. Geisinger has part­nered with Re­gen­eron Ge­net­ics Cen­ter, a bio­phar­ma­ceu­ti­cal com­pany in Tar­ry­town, N.Y., to gen­er­ate clin­i­cal re­ports with test­ing re­sults. that are put into the EHR and pro­vided to pa­tients, who are then of­fered ge­netic coun­sel­ing.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.